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Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell
carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator of tumour growth, we explored the
potential benefit of COX-2 inhibition in combination with VEGFR inhibition in attempts at delaying tumour progression on Su.
Methods: COX-2 expression was compared with areas of hypoxia in tumours that progressed on Su vs untreated tumours. Mice
bearing human cRCC xenografts were treated with Su and the COX-2 inhibitor, celecoxib, and the effects on tumour growth were
assessed. Sequential vs concurrent regimens were compared.
Results: COX-2 expression was increased in cRCC xenografts in areas of tumour hypoxia. The combination of Su and celecoxib
achieved longer times to tumour progression compared to treatment with either agent alone or to untreated control animals in
four models. This effect was seen with concurrent but not with sequential therapy.
Conclusion: COX-2 inhibition can extend the effectiveness of VEGFR inhibition. This effect is dependent on the timing of therapy.
Clinical trials combining Su and COX-2 inhibitors should be considered as a means delaying time to progression on sunitinib in
patients with metastatic cRCC.
Recently, several new agents targeting the VEGF pathway have
demonstrated significant activity in patients with advanced clear
cell renal cell carcinoma (cRCC). Sunitinib, sorafenib and
pazopanib are multi-tyrosine kinase inhibitors (TKI) whose targets
include vascular endothelial growth factor receptor-2 (VEGFR2)
and their activity is thought to be primarily based on their
inhibition of this target. In a first-line phase III trial in patients
with metastatic cRCC in which sunitinib was compared with
IFN-a, the response rate was 47% and the median progression-free
survival (PFS) was 11 months for sunitinib compared with a 12%
response rate and median PFS of 5 months for IFN-a (Motzer et al,
2009). Similar results were seen in a phase III clinical trial
comparing pazopanib to placebo (Sternberg et al, 2010). Axitinib,
another VEGFR TKI was recently added to the therapeutic
armentarium, while still another, tivozanib is currently under late
stage investigation (Rini et al, 2011; Motzer et al, 2012; Nosov et al,
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to enhance and/or prolong the effect of these agents are of
importance as responses are almost exclusively partial and tumours
develop tumour progression on therapy at a median of less than
1 year.
The mechanisms of resistance to VEGFR inhibition are not fully
understood and have been variably reported to involve restored
angiogenesis, inhibition of angiostatic pathways, and induction of
angiogenesis independent processes such as increased tumour
invasiveness and epithelial-to-mesenchymal transition (Casanovas
et al, 2005; Rini and Atkins, 2009; Bhatt et al, 2010; Hammers et al,
2010; Huang et al, 2010). Understanding the mechanism of
resistance may not only guide subsequent treatment selection, but
may also provide insights into optimal upfront combination
treatment approaches.
Cyclooxygenase-2 (COX-2) is an enzyme in the pathway
leading to production of prostaglandin E2 (PGE2) and aracha-
donic acid (Ghosh et al, 2010). This pathway is known to play a
role in inflammation, tumour growth, invasiveness and metas-
tasis, inhibition of apoptosis and angiogenesis. Inhibition of
COX-2 has been shown to be a promising antitumour and
antiangiogenic strategy in several tumour types including RCC
(Hida et al, 2000; Song et al, 2002; Chen et al, 2004a; Arber et al,
2006). In preclinical models, COX-2 inhibition has been shown to
exhibit activity as a single agent as well as in combination with
immunotherapy and chemotherapy (Veltman et al, 2010; Legge
et al, 2011; Vivaldi et al, 2012). COX-2 inhibitors have also been
studied in combination with interferon-a therapy in patients with
advanced cRCC. Although initial reports suggested improved
response rates for patients bearing high COX-2 expressing
tumours, a subsequent study of the combination of a COX-2
inhibitor and interferon-a confined to this patient population did
not substantiate a significant benefit for the combination relative
to interferon alone. The value of COX-2 inhibition in combina-
tion with VEGFR TKIs has not been formally studied in patients
with RCC.
We have previously developed murine models of acquired
tumour resistance to VEGFR TKI therapy using human cRCC
xenografts. One of these models utilises tumour tissue directly
obtained from a patient at the time of nephrectomy for cRCC. The
tumour model MDA-62 is a xenograft model of cRCC developed
from a tumour fragment harvested from a patient with locally
advanced cRCC. Thus, unlike the cell line models that are of clonal
origin, this low passage xenograft may better represent tumour
heterogeneity noted in the human condition. In this study we
explored the role of COX-2 in these models by assessing tumour
expression of COX-2 in tumour that have progressed while on
sunitinib and studying the effects of the combination of sunitinib
and the selective COX-2 inhibitor, celecoxib.
MATERIALS AND METHODS
Tumour xenograft induction. For subcutaneous xenografts the
following models were used: A498, 786-O: human cRCC cell lines
(ATCC, Manassas, VA, USA), UMRC-3 (Grossman et al, 1985)
and MDA-62 a primary tumour from a patient with locally
advanced clear cell RCC that was propagated subcutaneously in
mice for three passages prior to cryopreservation (Karam et al,
2011). Female nude beige mice (Charles River Laboratories,
Wilmington, MA, USA), 6–8 weeks of age and 20g average body
weight, were used. The mice were housed and maintained in
laminar flow cabinets under specific pathogen-free conditions. All
experiments were approved by the Institutional Animal Care and
Use Committee (IACUC) at Beth Israel Deaconess Medical Center.
To produce tumours, renal cancer cells were harvested from
subconfluent cultures by a brief exposure to 0.25% trypsin and
0.02% EDTA. Trypsinization was stopped with medium containing
10% FBS, and the cells were washed once in serum-free medium
and resuspended in PBS. Only suspensions consisting of single cells
with 490% viability were used for the injections.
Cells were injected subcutaneously (1 10
7cells) into the flanks
of the mice. Tumours developed in 480% of the mice and were
usually visible within a few days of implantation and once they
reached a diameter of 3–5mm, were measured daily to ensure a
consistent size at the outset of treatment. Vehicle, sunitinib
(additive-free, 53.6mgkg
 1 daily by gavage), celecoxib
(50mgkg
 1 daily by gavage) (Farooqui et al, 2007; Park et al,
2008; Li et al, 2011), or the combination was begun when the
tumours had grown to a diameter of 12mm as per our previous
reports (Bhatt et al, 2010; Zhang et al, 2011). Tumours were
measured daily during therapy to determine growth curves.
In all, 12mm was used as the pre-specified treatment start size
in the 786-O and A498 models in part because this size of tumour
may be sufficiently large to be proportionately comparable to a
lesion in the human clinical setting, but not too large to prevent a
period of several weeks before the mice would need to be sacrificed
at the end point of 20mm tumour size. It is also an optimal size for
tumour perfusion imaging, which is difficult to perform on smaller
tumours. Growth by 2mm from this baseline is the minimal
reproducible change in tumour size that could be accurately
measured by our calipers. Time to increase by 2mm was defined as
time to tumour progression. This approach is roughly equivalent to
the increase in tumour size (20% increase in long axis) that would
classify a patient as having progressive disease by RECIST criteria
(and therefore, treatment resistance) while receiving such therapy,
as it represents a 17% increase in diameter and 59% increase in
volume. Additionally, in our analysis, the tumour growth curves
showed similar results with both tumour volume and long axis
measurements (Figures 2A and B). In this model, progression also
correlates with the resumption in tumour perfusion that follows an
initial reduction in perfusion, seen in our prior studies (Schor-
Bardach et al, 2009; Bhatt et al, 2010).
Treatment was continued until tumours grew to 20mm in long-
axis diameter (i.e., the maximum allowable growth by IACUC) at
which point the mice were sacrificed. Tumour tissue from
sunitinib, celecoxib, and untreated tumours was obtained at
20mm for various analyses described below. Sunitinib-treated
tumours that grew beyond 14mm and grew to the end point of
20mm size despite continued treatment were defined as ‘Resistant
to sunitinib’.
In the studies with UMRC-3 and MDA-62, treatment was
started when tumours reached a size of 5mm in maximum
diameter. Tumour size was measured daily and mice were
sacrificed after 30 days of treatment. The pretreatment tumour
size was less in this model because the study design differed from
the xenograft model in which imaging was performed at 12mm for
optimal imaging resolution.
Immunohistochemistry. For hypoxia analysis, animals were
injected intraperitoneally with Hypoxyprobe (Pimonidazole HCl:
Hypoxyprobe store, NPI, Cat # HP1-100 kit, Burlington, MA,
USA) 100ml 2h prior to sacrifice. For COX-2 and Hypoxyprobe
analysis, 4mm thick sections were prepared from formalin-fixed,
paraffin-embedded tumour specimens. Sections were deparaffi-
nized, rehydrated and heated with a pressure cooker to 1251C for
30s in citrate buffer for antigen retrieval. After cooling to room
temperature, sections were incubated in 3% hydrogen peroxide for
5min to quench endogenous peroxidase, (Dako, Carpinteria, CA,
USA). The primary antibodies (anti-COX-2 antibody from Cay-
man Chemical, Ann Arbour, MI, USA, Cat #160112; anti-
Hypoxyprobe antibody from Natural Pharmacia International,
Burlington, MA, USA, Cat#FITC-MAb1) were applied at a 1:50
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incubation with Dako EnVisionþ System HRP labelled polymer
anti-mouse (Dako, Cat# K4006) for 30min followed by incubation
with DAB chromogen. Slides were slightly counterstained with
hematoxylin. Slides were scanned using the Scanscope XT (Aperio
Technologies Inc., Visa, CA, USA).
Tumour perfusion imaging. Tumour perfusion imaging with
arterial spin-labelling MRI (ASL MRI) was performed as previously
described (Bhatt et al, 2010). Briefly mice were anaesthetized, and
placed in the supine position on a 3-cm diameter custom-built
surface coil. Images were acquired using a 3.0T whole-body
clinical MRI scanner (3T HD; GE Healthcare Technologies,
Waukesha, WI, USA). A single slice ASL image was obtained with
a single-shot fast spin echo sequence (SSFSE) using a background-
suppressed, flow-sensitive alternating inversion-recovery strategy.
Twenty-four label and control pair images were acquired and
averaged for the ASL acquisition. A reference proton density image
was acquired by turning off all background suppression and
labelling pulses in the ASL preparation. T1 measurement was
performed by using the same imaging sequence at same slice
location but with inversion recovery at different inversion times.
The single transverse slice of ASL was carefully positioned at the
centre of the tumour, which was marked on the skin with a
permanent marker pen for follow-up MRI studies. ASL raw data
were reconstructed and converted to quantitative tumour perfusion
maps using automated, custom software written within the
Interactive Data Language (IDL; ITT visual Information Solutions,
Boulder, CO, USA) (Alsop and Detre, 1996). Regional analysis of
the perfusion images was performed with Image-J software (Image
Processing and Analysis in Java; National Institutes of Health,
Bethesda, MD, USA). To determine tumour perfusion, a region of
interest was drawn freehand around the peripheral margin of the
tumour by using an electronic cursor on the reference image that
was then copied to the perfusion image. The mean blood flow
for the tumour tissue within the region of interest was derived.
A 16-colour table was applied in 10ml per 100g per min
increments ranging from 0 to 160ml per 100g per min, with flow
values represented as varying shades of black, blue, green, yellow,
red, and purple, in order of increasing perfusion.
Statistical analysis. The primary end point was time to progres-
sion (TTP). TTP was defined as time in days to increase by 2mm
in tumour size and compared between groups via the exact
Wilcoxon rank sum test. Median TTP in days and ranges are
reported throughout.
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Figure 1. Sunitinib resistance is accompanied by enhanced COX-2 expression in areas of tumour hypoxia. Representative low (A, C, E, G, I, K, M,
O) (scale bar¼300mM) and high (B, D, F, H, J, L, N, P) (scale bar¼100mM) magnification microscopic images of cRCC xenografts analysed by
immunohistochemistry. 786-O tumours treated with sunitinib (A–D) or vehicle (E–H) and A498 tumours treated with sunitinib (I–L) or vehicle (M–P)
were immunostained for Hypoxyprobe (A, B, E, F, I, J, M, N) or COX-2 (C, D, G, H, K, L, O, P).
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Sunitinib-treated tumours exhibit enhanced hypoxia which
correlates with COX-2 expression. Since sunitinib treatment
reduces tumour blood flow (Bhatt et al, 2010; Zhang et al, 2011),
we assessed the effect of this agent on tumour hypoxia. We found
that sunitinib treatment of either A498 or 786-O tumours leads to
tumour hypoxia which is present, as shown in Figure 1, at the time
of resistance to sunitinib. Pimonidazole HCl-positive hypoxic
tumour cells are consistently observed around areas of tumour
necrosis (Figure 1A, B, I, and J) while only scattered hypoxic
tumour cells are detected in untreated tumours (Figure 1E, F, M,
and N). As COX-2 expression is known to be induced by hypoxia,
we also assessed the COX-2 expression in suntinib resistant
tumours. As shown in Figure 1, both 786-O (Figures 1C and D)
and A498 (Figure 1K and L) suntinib resistant tumours exhibit a
spatially regulated area of increased COX-2 expression, with
maximal expression in the hypoxic tumour cells surrounding areas
of necrosis in 786-O (C,D) and A498 (K,L) tumours. In contrast,
consistent with the absence of significant tumour hypoxia, COX-2
expression does not occur in such a specific pattern in vehicle-
treated tumours of the same size. Untreated tumours did
not exhibit hypoxia and showed diffuse COX-2 expression
(Figure 1E–H and M–P). Thus, sunitinib resistance is accompanied
by an increase in COX-2 expression levels in areas of hypoxic
tumour cells.
Combining COX-2 inhibition with sunitinib enhances anti-
tumour efficacy and delays disease progression on sunitinib.
We hypothesised that the increased COX-2 expression seen in
sunitinib resistant tumours might indicate a role for COX-2
inhibition in enhancing efficacy of and/or delaying tumour
progression on sunitinib. Mice harbouring A498 and 786-O
xenografts were treated with vehicle, sunitinib, celecoxib, or
sunitinibþcelecoxib. Figure 2A–C show the tumour growth by
tumour volume, length, and time to progression in the four
treatment arms in the mice bearing A498 tumours. The
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Figure 2. Celecoxib enhances the anti-tumour activity of sunitinib in two cRCC models. Growth curves in tumour volume (A) and tumour size (long
axis) (B) of A498 derived tumours treated with vehicle (n¼3), sunitinib (n¼5), celecoxib (n¼3) or celecoxibþsunitinib (n¼6) are shown as
average±s.e.m. (C) In mice bearing the A498 tumour, the combination of celecoxibþsunitinib showed a longer time to progression than
treatment with sunitinib alone 34.5 (27–45) days, n¼6 and 20 (15–27) days, n¼5, respectively, P¼0.006). (D) Mice bearing 786-O tumours also
exhibit a significant prolongation in time to progression with the combination of celecoxibþsunitinib relative to sunitinib alone (16 (12–19) days,
n¼7 and 12 (10–13) days, n¼7, respectively, P¼0.007). For box plots themselves, the thick horizontal line within each box is the median value;
the upper and lower boundaries of the boxes are the 75th and 25th percentiles. The bars above and below the boxes are placed at the observed
values closest to the 75th percentile plus 1.5 times the interquartile range (75th percentile minus 25th percentile) and closest to the 25th percentile
minus 1.5 times the interquartile range; observations outside those limits are plotted separately and represented with a small circle.
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progression than treatment with sunitinib alone (median (range):
34.5 (27–45) days, n¼6 vs 20 (15–27) days, n¼5, respectively,
P¼0.006). The vehicle arm and the celecoxib single agent arm
showed shorter times to progression of 5 (4–7) days, n¼3 vs 13
(9–14) days, n¼3. Figure 2D shows that mice bearing 786-O
tumours also exhibit a significant prolongation in time to
progression with the combination of sunitinibþcelecoxib relative
to sunitinib alone (median (range) 16 (12–19) days, n¼7 vs 12
(10–13) days, n¼7, respectively, P¼0.007). The vehicle arm and
the celecoxib single agent arm showed time to progression of 7
(6–10) days, n¼5 vs 11.5 (10–12) days, n¼5, respectively.
To further confirm these results, two additional RCC models
were used, the UMRC-3 cell line model and the MDA-62 patient
tumour derived model. As shown in Figure 3, celecoxib alone had
little impact on the growth rate in these models. The combination
of celecoxib and sunitinib also showed improved efficacy vs single
agent sunitinib.
Concurrent therapy is superior to sequential therapy. To assess
the temporal relationship between sunitinib and celecoxib admin-
istration, we compared adding celecoxib vs switching to celecoxib
at the time of initial tumour progression on sunitinib in the 786-O
model and determined the time to increase by another 2mm in
long axis. Figure 4 shows that switching to celecoxib (Sunitinib-
Celecoxib) is significantly worse than continuous sunitinib
(sunitinib continuous) (median (range) 10 (5–10) days, n¼6 vs
12 (10–13) days, n¼7, respectively, P¼0.003) and that delayed
addition of celecoxib (sunitinib-celecoxibþsunitinib) (median
(range) 10 (7–13) days, n¼7) did not improve the efficacy of
continuous sunitinib. Thus, early administration of celecoxib
appears to be necessary for it to enhance the efficacy of sunitinib
therapy in this model.
Celecoxib augments the activity of sunitinib in an angiogenesis-
independent manner. As celecoxib has been shown to exhibit
antiangiogenic activities in addition to many other antitumour
activities, we first assessed the effects of celecoxib on the
antiangiogenic activity of sunitinib. Tumour perfusion was
measured in the 786-O tumour model by ASL MRI, a technique
which correlates with microvascular density, at days 0, 2, 4, and 8
(Figure 5). While sunitinib (n¼2) treatment led to a pronounced
drop in tumour perfusion at all time points compared with vehicle
(n¼3), celecoxib (n¼2) did not decrease tumour perfusion as a
single agent or further decrease perfusion when added to sunitinib
(n¼3). Although sample sizes are small, preventing statistical
power, trends are apparent. Representative perfusion images of a
single tumour slice are shown in Figure 5B.
DISCUSSION
In this study we show that resistance to sunitinib is accompanied
by increased COX-2 expression in areas of tumour hypoxia in two
cRCC xenograft models. We also show that the COX-2 inhibitor
celecoxib enhances the effectiveness of sunitinib in four cRCC
xenograft models by delaying time to progression when adminis-
tered early in the course of sunitinib therapy. Celecoxib as a single
agent showed activity only in the 786-O tumour model. However,
in all models the combination of sunitinib and celecoxib showed
greater inhibition of tumour growth than either agent alone. The
MDA-62 model may be more relevant to patients as the xenograft
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implanted directly into the subcutaneous space of female BALB/c
nude mice and serially passaged into new mice without ever being
propagated in vitro. Because it is not clonal in origin, but rather
developed from a fragment of human tumour, it may be more
reflective the heterogeneity in tumour biology associated with the
human condition. Although different pretreatment sizes were used
in the patient tumour model and xenograft models due to
differences in imaging requirements, similar treatment trends were
obtained. In general the effects of treatment are more pronounced
when tumours are smaller prior to treatment. Further experiments
to clarify the differences in effect vs pretreatment sizes should be
considered. Experiments with this human tumour model further
strengthen the findings noted with the clonally derived cell lines.
COX-2 inhibition has been shown to have antitumour activity
in cRCC and is postulated to function via a variety of antitumour
and antiangiogenic mechanisms (Chen et al, 2004a and b; Sato
et al, 2010). COX-2 expression has also been reported to correlate
with cRCC prognosis. Although the precise relationship is not well-
understood, most published studies report COX-2 expression to
correlate with poor clinicopathologic features and predict a poor
prognosis (Miyata et al, 2003; Tuna et al, 2004; Sozen et al, 2008; Li
et al, 2009). One report, however, found that COX-2 expression
predicted for a longer median overall survival (Kankuri-
Tammilehto et al, 2010). While it remains unclear how to reconcile
these seemingly disparate findings, it is possible that the
discrepancies could relate to the clinical context in which the
tissue was obtained. In this regard, our studies showing enhanced
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adjacent to areas of tumour necrosis, suggest that this expression
may be both heterogeneous and inducible as a consequence of
VEGFR TKI-induced hypoxia within the cRCC xenografts. In this
study we cannot rule out the possibility that COX-2 expression
appears to be increasing in areas of hypoxia and actually decreasing
in non-hypoxic areas. This possibility is less likely since COX-2 is
known to be positively regulated by hypoxia.
COX-2 inhibition has also been studied in clinical
trials of patients with advanced cRCC. Rini et al (2006) have
examined the relationship between COX-2 expression and
response to celecoxib and interferon-a in phase II trials
(Schwandt et al, 2011). An initial trial in patients with metastatic
cRCC introduced the hypothesis that maximal COX-2 immunos-
taining may directly correlate with response to the combination
(Rini et al, 2006). However, a subsequent study of the combination
confined to patients with high COX-2 expressing tumours did not
substantiate a significant benefit for the combination relative to
interferon alone (Schwandt et al, 2011). Another clinical trial
combining the COX-2 inhibitor, meloxicam, and IFN-a in 43
patients with metastatic cRCC showed an overall response rate of
37.2% with a median time to progression of 14 months (Shinohara
et al, 2009). However, at this point, no clinical studies have
examined the role of COX-2 inhibition in combination with a
VEGFR TKI.
Evasive resistance to antiangiogenic therapy in cRCC is likely
multi-factorial. Several potential mechanisms of resistance have
recently been reported (Casanovas et al, 2005; Rini and Atkins,
2009; Bhatt et al, 2010; Hammers et al, 2010; Huang et al, 2010).
We have shown that VEGFR blockade results in prompt
tumour devascularisation and likely hypoxia-driven tumour
necrosis(Schor-Bardach et al, 2009). Thus, upregulation of
hypoxia-mediated mechanisms of resistance is likely an early
event post-VEGFR TKI therapy. Although our prior studies have
shown that resumed angiogenesis and restored perfusion was one
mechanism of acquired resistance to sunitinib, we did not find that
administration of celecoxib led to decreased perfusion by ASL MRI
in our models. Thus, celecoxib is likely acting by a distinct
mechanism from sunitinib, which potently reduces tumour
perfusion. It is conceivable that as VEGFR blockade persists, the
mechanisms contributing to resistance become more diverse. Our
timing experiments show that the activity of celecoxib depends on
dynamic changes induced by sunitinib treatment. Further experi-
ments in tumour models that include tumour cell-endothelial cell
interactions are needed and are planned.
Optimally, in the future, application of surrogate biomarkers
such as PGE-M, a urinary metabolite of PGE2 (Murphey et al,
2004; Johnson et al, 2006; Reckamp et al, 2011), might enable
institution of treatment at the time of COX-2 upregulation, thereby
sparing the cost and toxicity associated with upfront combination
therapy. If a biomarker for COX-2 activity were available, patients
with metastatic RCC being treated with a VEGFR pathway
inhibitor could be monitored over the course of therapy and
celecoxib added at the time of biomarker elevation and compared
with continued VEGFR pathway inhibitor alone. However, in the
absence of such biomarkers, our data support the study of the
initial combination of celecoxib and sunitinib in patients with
advanced cRCC.
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